Thursday, July 5, 2018

MabVax Therapeutics Grants License To Y-mAbs Therapeutics

San Diego-based MabVax Therapeutics said this week that it has granted a sublicense for its technology, to Y-mAbs Therapeutics, a clinical stage biopharmaceuticals company. According to MabVax, it has granted an exclusive sublicense to a bi-valent ganglioside based vaccine intended to treat neuroblastoma, a rare pediatric cancer. MabVax said the deal is worth $1.3M, plus additional amounts possible if the FDA approves the vaccine from Y-mAbs. The company said the neuroblastoma vaccine was originally developed by Dr. Philip Livingston and colleagues at Memorial Sloan Kettering Cancer Center (MSK) and licensed as part of a broader portfolio of anti-cancer vaccines to MabVax.